First in human development of oligonucleotide drugs requires careful safety evaluation as molecular complexity increases. In this webinar, ICON specialists discuss best practices for FIH ON study design and risk mitiga...
- Home
- News & Events
- Events
- Webinars
Webinars
-
Webinars
FDA Waivers for TQT Studies
Date 8 December 2015 Time 10:00 - 11:00 Location Webinar Timezone America/Lima
ICON’s Webinar Channel
A library of recorded webinars exploring topics ranging from early to late phase.